AI-enabled biotech startup analysis

We send periodic emails with analyses of biotech startups and scientific papers. You can find the analyses we've done thus far below (we started doing this in October 2023).

We use AI tools to write 95%+ of the text in these reports, with some light manual editing and a bit of human commentary here or there.






Startup analyses

This is not investment advice. AI does the research and writes the text. We proofread and fact-check each article, though we can't guarantee the analysis is 100% accurate. We are shooting for comprehensive yet concise first-pass review of companies.



Designing a Phase 3 in HS

Analyzed on March 28, 2024

High-level design of a potential Phase 3 trial in hidradenitis suppurativa

Designing a Phase 3 in CSU

Analyzed on March 28, 2024

High-level design of a potential Phase 3 trial in chronic spontaneous urticaria

Contineum Therapeutics

Analyzed on March 20, 2024

Latest raise: Filed for IPO, March 2024

Stage: Phase 2

Indications: Immunology and inflammation

Modality: Small molecule

Alumis

Analyzed on March 7, 2024

Latest raise: $259M Series C, March 2024

Stage: Phase 2

Indications: Immunology

Modality: Small molecule

Sionna Therapeutics

Analyzed on March 7, 2024

Latest raise: $182M Series C, March 2024

Stage: Phase 1

Indications: Cystic Fibrosis

Modality: Small molecule

Boundless Bio

Analyzed on March 7, 2024

Latest raise: Filed for IPO, March 2024

Stage: Phase 2

Indications: Oncology

Modality: Small molecule

Viking Phase 2 obesity

Analyzed on March 1, 2024

Comparing Viking's GLP-1 data to Novo's oral GLP-1 data

Ironwood Phase 3 SBS

Analyzed on March 1, 2024

Analyzing Ironwood's Phase 3 in short bowel syndrome

Boehringer / Zealand Phase 2 MASH

Analyzed on March 1, 2024

Analyzing Boehringer / Zealand Pharma's Phase 2 in MASH

Janux Phase 1 results

Analyzed on March 1, 2024

Analyzing Janux's Phase 1 data in solid tumors

Palatin Phase 3 results

Analyzed on March 1, 2024

Analyzing Palatin's Phase 3 data in dry eye disease

EyeBio Phase 1/2 results

Analyzed on February 22, 2024

Analyzing EyeBio's Phase 1/2 results in diabetic macular edema and wet AMD

Profound Bio

Analyzed on February 14, 2024

Latest raise: Series B, February 2024

Stage: Phase 2

Indications: Oncology

Modality: Antibody-drug conjugate

Neurona Therapeutics

Analyzed on February 14, 2024

Latest raise: Late stage private round, February 2024

Stage: Phase 2

Indications: Neurological disease

Modality: Cell therapy

Accent Therapeutics

Analyzed on February 7, 2024

Latest raise: Series C, February 2024

Stage: Preclinical

Indications: Oncology

Modality: Small molecule

LB Pharmaceuticals

Analyzed on February 7, 2024

Latest raise: Series C, February 2024

Stage: Phase 2

Indications: Psychiatry

Modality: Small molecule

Basking Biosciences

Analyzed on February 7, 2024

Latest raise: Private financing, February 2024

Stage: Phase 2

Indications: Cardiovascular disease

Modality: Aptamer

Invea Therapeutics

Analyzed on January 30, 2024

Latest raise: Filed for IPO, January 2024

Stage: Phase 1

Indications: Immunological disease, Inflammatory disease

Modality: Small molecules

Fractyl Health

Analyzed on January 30, 2024

Latest raise: Filed for IPO, January 2024

Stage: Phase 3

Indications: Obesity, Diabetes

Modality: Device, Gene therapy

Kyverna Therapeutics

Analyzed on January 16, 2024

Latest raise: Filed for IPO, January 2024

Stage: Phase 2

Indications: Autoimmune disease

Modality: Cell therapy

Alto Neuroscience

Analyzed on January 16, 2024

Latest raise: Filed for IPO, January 2024

Stage: Phase 2

Indications: Psychiatry, Neurology

Modality: Small molecules

Vico Therapeutics

Analyzed on January 16, 2024

Latest raise: $60M Series B, January 2024

Stage: Phase 2

Indications: Rare disease, Neurology

Modality: Antisense oligonucleotides

OnCusp Therapeutics

Analyzed on January 16, 2024

Latest raise: $100M Series A, January 2024

Stage: Preclinical

Indications: Oncology, Hematology

Modality: Antibody-drug conjugates, Monoclonal antibody

HI-Bio

Analyzed on January 16, 2024

Latest raise: $95M Series B, January 2024

Stage: Phase 2

Indications: Renal disease, Autoimmune disease

Modality: Monoclonal antibody

Metagenomi Technologies

Analyzed on January 8, 2024

Latest raise: Filed for IPO, January 2024

Stage: Preclinical

Indications: Hematology, Cardiovascular disease, Rare disease, Autoimmune disease

Modality: Gene editing, Cell therapy

ArriVent Biopharma

Analyzed on January 8, 2024

Latest raise: Filed for IPO, January 2024

Stage: Phase 3

Indications: Oncology

Modality: Small molecules

CG Oncology

Analyzed on January 8, 2024

Latest raise: Filed for IPO, January 2024

Stage: Phase 3

Indications: Oncology

Modality: Viral therapy

Tome Biosciences

Analyzed on December 13, 2023

Latest raise: $213M Series A + B, Dec 2023

Stage: Preclinical

Indications: Liver disease, Rare disease, Autoimmune disease

Modality: Gene editing

Carmot Therapeutics

Analyzed on December 4, 2023

Latest raise: Acquired by Roche for $2.7B upfront, November 2023

Stage: Phase 2

Indications: Obesity, Diabetes

Modality: Peptides, Small molecules

Odyssey Therapeutics

Analyzed on November 14, 2023

Latest raise: $101M Series C, Dec 2023

Stage: Preclinical

Indications: Inflammatory disease, Autoimmune disease, Cancer

Modality: Small molecules, Antibodies

Seismic Therapeutics

Analyzed on December 4, 2023

Latest raise: $121M Series B, Dec 2023

Stage: Preclinical

Indications: Autoimmune

Modality: Protease, Bispecific antibody

MBrace Therapeutics

Analyzed on November 14, 2023

Latest raise: $85M Series B, Nov 2023

Stage: Phase 1

Indications: Solid tumors

Modality: ADC

Kynexis Therapeutics

Analyzed on November 14, 2023

Latest raise: $57M Series A, Nov 2023

Stage: Preclinical

Indications: Cognitive Impairment Associated With Schizophrenia

Modality: Small molecule

EyeBio

Analyzed on November 14, 2023

Latest raise: $130M Series A, Nov 2023

Stage: Phase 1/2

Indications: DME, Wet AMD

Modality: Tri-specific antibody

CARGO Therapeutics

Analyzed on November 8, 2023

Latest raise: $281M IPO, Nov 2023

Stage: Phase 2

Indications: Large B-cell lymphoma, Pediatric acute lymphoblastic leukemia, B-cell malignancies

Modality: CAR-T

OrsoBio

Analyzed on November 6, 2023

Latest raise: $60M Series A, Nov 2023

Stage: Phase 2

Indications: Type 2 Diabetes, Obesity, Severe dyslipidemias, Lipodystrophies, Organ failure

Modality: Small molecules

Gate Bioscience

Analyzed on November 6, 2023

Latest raise: $60M Series A, Nov 2023

Stage: Discovery

Indications: N/A

Modality: Small molecules

MapLight Therapeutics

Analyzed on October 31, 2023

Latest raise: $225M Series C, Oct 2023

Stage: Phase 2

Indications: Schizophrenia, Autism, Alzheimer's disease psychosis, dyskinesias

Modality: Small molecules

Function Oncology

Analyzed on October 31, 2023

Latest raise: $28M Series A, April 2023

Stage: Discovery

Indications: Oncology

Modality: N/A

Triveni Bio

Analyzed on October 31, 2023

Latest raise: $92M Series A, Oct 2023

Stage: Preclinical

Indications: Atopic dermatitis

Modality: Monoclonal antibodies

Aiolos Bio

Analyzed on October 24, 2023

Latest raise: $245M Series A, Oct 2023

Stage: Phase 2

Indications: Asthma, COPD, CSU

Modality: Monoclonal antibodies

Agomab Therapeutics

Analyzed on October 17, 2023

Latest raise: $100M Series C, Oct 2023

Stage: Phase 2

Indications: Fibrostenosing Crohn's disease, IPF, fibrosis

Modality: Small molecules, Monoclonal antibodies

Neumora Therapeutics

Analyzed on October 3, 2023

Latest raise: $250M IPO, Sept 2023

Stage: Phase 3

Indications: Depression, Bipolar depression, Alzheimer's disease, Schizophrenia, Parkinson's disease

Modality: Small molecules

Rampart Bio

Analyzed on October 25, 2023

Latest raise: $85M Series A, Oct 2023

Stage: Preclinical

Indications: Hypophosphatasia

Modality: Gene therapy

MinervaX

Analyzed on October 17, 2023

Latest raise: $57M, Oct 2023

Stage: Phase 2

Indications: Group B streptococcal vaccine

Modality: Vaccine

AstronauTx

Analyzed on October 17, 2023

Latest raise: $61M Series A, Oct 2023

Stage: Discovery

Indications: Alzheimer's disease

Modality: Undisclosed

Amplifier Therapeutics

Analyzed on October 23, 2023

Latest raise: $33M Series A, Oct 2023

Stage: Phase 1

Indications: Cardiometabolic diseases

Modality: Small molecule


Scientific paper analyses